fluoxetine has been researched along with Diabetes Mellitus in 14 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the effect of fluoxetine, a specific serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight." | 9.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| "Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e." | 6.71 | Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005) |
| "To study the effect of fluoxetine, a specific serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight." | 5.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| "In comorbid diabetes mellitus and depression, most evidence supports the use of fluoxetine in control of glucose handling." | 4.81 | Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. ( Goodnick, PJ, 2001) |
| "Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e." | 2.71 | Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005) |
| "Weight reduction is essential in the management of most non-insulin-dependent diabetics, but this therapeutical goal is difficult to obtain." | 2.68 | Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. ( Daubresse, JC; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1996) |
| "Body weight was kept constant." | 2.67 | Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. ( Frölich, M; Krans, HM; Meinders, AE; Potter van Loon, BJ; Radder, JK; Zwinderman, AH, 1992) |
| "Fluoxetine is an inhibitor of serotonin re-uptake which has been found to produce weight loss in humans and animals." | 2.67 | A randomized double-blind clinical trial of fluoxetine in obese diabetics. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992) |
| "Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved." | 2.67 | Fluoxetine therapy in obese diabetic and glucose intolerant patients. ( Daubresse, JC; Friedman, H; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1992) |
| "Treating leptin-deficient ob/ob and leptin receptor-deficient db/db mice with fluoxetine did not normalize body weight or rescue fertility, perhaps due to altered serotonergic tone in these animals." | 1.31 | Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction? ( Clayton, AH; Howard, LC; Moenter, SM; Sullivan, SD, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bez, Y | 1 |
| Coffey, BJ | 1 |
| Aswar, U | 1 |
| Chepurwar, S | 1 |
| Shintre, S | 1 |
| Aswar, M | 1 |
| Isaac, R | 1 |
| Boura-Halfon, S | 1 |
| Gurevitch, D | 1 |
| Shainskaya, A | 1 |
| Levkovitz, Y | 1 |
| Zick, Y | 1 |
| Lustman, PJ | 1 |
| Clouse, RE | 1 |
| Andersen, SW | 1 |
| Clemow, DB | 1 |
| Corya, SA | 1 |
| Theleritis, CG | 1 |
| Papadimitriou, GN | 1 |
| Papageorgiou, CC | 1 |
| Dikeos, DG | 1 |
| Masdrakis, V | 1 |
| Kostoulas, C | 1 |
| Psarros, C | 1 |
| Soldatos, CR | 1 |
| Connolly, VM | 1 |
| Gallagher, A | 1 |
| Kesson, CM | 1 |
| Daubresse, JC | 2 |
| Kolanowski, J | 2 |
| Krzentowski, G | 2 |
| Kutnowski, M | 2 |
| Scheen, A | 2 |
| Van Gaal, L | 2 |
| Maheux, P | 1 |
| Ducros, F | 1 |
| Bourque, J | 1 |
| Garon, J | 1 |
| Chiasson, JL | 1 |
| Goodnick, PJ | 1 |
| Sullivan, SD | 1 |
| Howard, LC | 1 |
| Clayton, AH | 1 |
| Moenter, SM | 1 |
| Potter van Loon, BJ | 1 |
| Radder, JK | 1 |
| Frölich, M | 1 |
| Krans, HM | 1 |
| Zwinderman, AH | 1 |
| Meinders, AE | 1 |
| Gray, DS | 1 |
| Fujioka, K | 1 |
| Devine, W | 1 |
| Bray, GA | 1 |
| Friedman, H | 1 |
2 reviews available for fluoxetine and Diabetes Mellitus
| Article | Year |
|---|---|
Treatment of depression in diabetes: impact on mood and medical outcome.
Topics: Behavior Therapy; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Diabetes Mellitus; Flu | 2002 |
Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Glucose; Clinical Trials as T | 2001 |
7 trials available for fluoxetine and Diabetes Mellitus
| Article | Year |
|---|---|
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Depressive Disorder, | 2005 |
A study of fluoxetine in obese elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Evaluation S | 1995 |
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dou | 1996 |
Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine | 1997 |
Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose; Glu | 1992 |
A randomized double-blind clinical trial of fluoxetine in obese diabetics.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Femal | 1992 |
Fluoxetine therapy in obese diabetic and glucose intolerant patients.
Topics: Blood Glucose; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose Tolerance Test; G | 1992 |
5 other studies available for fluoxetine and Diabetes Mellitus
| Article | Year |
|---|---|
Fluoxetine-Induced Serum Sickness-Like Reaction in an Adolescent with Obsessive Compulsive Disorder and Diabetes.
Topics: Adolescent; Diabetes Mellitus; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Selective Serotoni | 2021 |
Telmisartan attenuates diabetes induced depression in rats.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzimidazoles; Benzoates; Brain; Depress | 2017 |
Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells.
Topics: Animals; Apoptosis; Cell Death; Cell Line; Diabetes Mellitus; Fluoxetine; Humans; Insulin; Insulin R | 2013 |
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes | 2006 |
Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction?
Topics: Animals; Body Weight; Diabetes Mellitus; Eating; Estrous Cycle; Fasting; Female; Fertility; Fluoxeti | 2002 |